Key result
Empagliflozin significantly reduced the recurrence of atrial fibrillation from 6.5 to 2.3 episodes per patient-year (p=0.001) in diabetic patients with an ICD.
Why the study?
Patients with diabetes have an increased risk of AF, and SGLT2 inhibitors have shown pleiotropic cardiovascular effects particularly in heart failure, prompting evaluation of empagliflozin in patients with AF and type 2 diabetes.
Observational (n=23)
No
Absolute Event Rate: 2.3% vs 6.5%
p-value: p=0.001
May support SGLT2i evaluation in diabetic AF; leaves open effects on AF burden or recurrence.
Background: Many studies have highlighted an increased risk of developing atrial fibrillation (AF) in diabetic patients. The SGLT2 inhibitors, in addition to glycaemic control, have shown pleiotropic effects on the cardiovascular system, proving to be particularly advantageous in patients with heart failure. In this study we evaluated a group of patients with paroxysmal AF (PAF) or persistent AF (PeAF) affected by type 2 diabetes and treated with empagliflozin.
No takes yet. Share an insight, caveat, or question.
Fazio et al. (2021) conducted an observational in Paroxysmal or persistent atrial fibrillation and type 2 diabetes (n=23). Empagliflozin vs. One year period before starting empagliflozin was evaluated on Recurrences of atrial fibrillation per patient-year (p=0.001). Empagliflozin significantly reduced the recurrence of atrial fibrillation from 6.5 to 2.3 episodes per patient-year (p=0.001) in diabetic patients with an ICD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: